Francesca Bonanni

Dr. Francesca Bonanni

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
FBFrancesca Bonanni
Francesca Bonanni
CSChiara Servoli
Chiara Servoli
GSGaia Spaziani
Gaia Spaziani
EBElena Bennati
Elena Bennati
CFChiara Di Filippo
Chiara Di Filippo
SFSilvia Favilli
Silvia Favilli
Early surgery and improved medical care have led to the increased survival of neonates with congenital heart disease (CHD), who now commonly reach adulthood. Among adults with CHD, a growing subgroup is represented by middle-aged and even elderly patients. In this elderly population, acquired cardiac and extracardiac comorbidities represent the main cause of morbidity and mortality; the control and correction of cardiovascular risk factors or an appropriate check for extracardiac complications (such as malignancies) is therefore of paramount importance. Complications and frailty syndrome appear to occur earlier in ACHD than in the general population due to a frequent discrepancy between chronological and biological age. Multiple stressors throughout life (hemodynamic abnormalities, cardiac operations and interventional procedures, the placement of foreign materials) that result in a chronic inflammatory response are among the leading causes of premature senescence. This review is aimed at assessing the characteristics and special needs of this elderly ACHD population with a view to proposing novel models for the organization of extended care.

25 April 2025 in JACC: Advances
Verified
Journal Article
Open access
FBFrancesca Bonanni
Francesca Bonanni
AFAnnamaria Del Franco
Annamaria Del Franco
VSValeria Setti
Valeria Setti
MCMatteo Casini
Matteo Casini
SSSamuele Salvi
Samuele Salvi
IOIacopo Olivotto
Iacopo Olivotto
A substantial proportion of hypertrophic cardiomyopathy (HCM) patients and negative genetic testing (Sarc-) have a positive family history of HCM (FH), suggesting a stronger genetic component. The purpose of this study was to assess whether Sarc-/FH+ patients differ from Sarc-/FH- and gene-positive (Sarc+) patients in terms of phenotype and prognosis. Six hundred fifty-four HCM patients underwent comprehensive clinical assessment and genetic testing, followed for a median of 6 years. The 3 groups (Sarc-/FH-, Sarc-/FH+, Sarc+) were compared for major arrhythmic events, heart failure, all-cause death, atrial fibrillation, and stroke. Of the 654 patients, 182 were Sarc-/FH- (28%), 101 were Sarc-/FH+ (15%), and 371 were Sarc+ (57%). Sarc-/FH+ were similar to Sarc+: they were younger, with higher HCM risk sudden cardiac death and lower prevalence of obstruction (age 43 [IQR: 23-53] years vs 39 [IQR: 23-52] years; P = 0.235; 19% obstructive vs 18%; P = 0.763) compared to Sarc-/FH-. However, Sarc-/FH+ were akin to Sarc-/FH- due to the lower prevalence of female sex, higher burden of cardiovascular risk factors, and less prevalent late gadolinium enhancement at cardiac magnetic resonance imaging (for female prevalence 26% vs 27%; P = 0.829; for late gadolinium enhancement in 50% vs 53%; P = 0.541), compared to Sarc+. There were no significant outcome differences, except for the incidence of stroke (2.7% for Sarc-/FH-, 1% for Sarc-/FH+, 5.9% for Sarc+, P = 0.046). Sarc-/FH+ represented 15% of our HCM cohort and exhibited intermediate clinical features between Sarc-/FH- and Sarc+, suggesting an interplay of monogenic/oligogenic disease with environmental factors. This population provides a unique opportunity for gene discovery and an understanding of nongenetic modifiers of HCM, deserving of dedicated investigation.

1 April 2026 in JACC: Heart Failure
Verified
Journal Article
Open access
FBFrancesca Bonanni
Francesca Bonanni
ACAdalgisa Cordisco
Adalgisa Cordisco
GCGiovanni Battista Calabri
Giovanni Battista Calabri
FGFrancesca Girolami
Francesca Girolami
IOIacopo Olivotto
Iacopo Olivotto
SFSilvia Favilli
Silvia Favilli

6 November 2025 in International Journal of Cardiology
Verified
Journal Article
Open access
FBFrancesca Bonanni
Francesca Bonanni
IGIgnazio Alessio Gueli
Ignazio Alessio Gueli
IBIrina Bellisario
Irina Bellisario
GTGiancarlo Todiere
Giancarlo Todiere
AAAlberto Aimo
Alberto Aimo
ABAndrea Barison
Andrea Barison
The classification of left ventricular cardiomyopathies is challenging due to evolving definitions and overlapping phenotypes. The European Task Force Criteria, by incorporating structural, functional, arrhythmic, and genetic parameters, refine the diagnostic criteria for arrhythmogenic cardiomyopathy. This study aimed to characterize the genotype-phenotype features of patients with arrhythmogenic left ventricular/biventricular cardiomyopathy (ALVC/ABVC), dilated cardiomyopathy (DCM), and their potential overlap. We retrospectively evaluated 306 patients with DCM or non-dilated left ventricular cardiomyopathy (NDLVC). Following European Task Force criteria, patients were reclassified as: isolated DCM, isolated ALVC/ABVC and a DCM-ALVC/ABVC overlapping phenotype. NDLVC not fulfilling the criteria, and isolated arrhythmogenic right ventricular cardiomyopathy were excluded. The study endpoint was a composite of cardiac death, sustained ventricular tachycardia, or ventricular fibrillation. Overall, 66, 79 and 76 patients were categorized as DCM, ALVC/ABVC, DCM-ALVC/ABVC, respectively. Genetic likely-pathogenic/pathogenic variants were more frequent in ALVC/ABVC than in DCM and DCM-ALVC/ABVC (50.6 % vs 28.8 % and 27.6 %, p = 0.004). DCM-ALVC/ABVC patients presented extensive LGE, higher NT-proBNP, and the highest arrhythmic burden (all p < 0.05). Moreover, they had significantly lower event-free survival (log-rank p = 0.002). In Cox analysis, LVEF (HR: 0.96, 95 % CI 0.94-0.99, p = 0.002) and LGE extent (HR: 1.04, 95 % CI 1.00-1.07, p = 0.016) independently predicted the endpoint. The European Task Force Criteria enabled the identification of an overlapping phenotype associated with increased arrhythmic risk, supporting the clinical utility of multiparametric diagnostic approaches to improve risk stratification and guide therapeutic decisions in patients with cardiomyopathies.

28 January 2026 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
FBFrancesca Bonanni
Francesca Bonanni
Angelo CapodiciAngelo Capodici
Angelo Capodici
FGFrancesco Gentile
Francesco Gentile
FMFrancesca Moschetti
Francesca Moschetti
CPClaudio PASSINO
Claudio PASSINO
AGAlberto Giannoni
Alberto Giannoni
Aims: Juvenile sudden cardiac death (SCD) is predominantly caused by inherited or congenital heart conditions. While structured screening programmes for competitive athletes are well established, current international guidelines emphasize a gap of evidence regarding the value of mass screening in the general youth population. This systematic review aimed to assess the effectiveness of large-scale screening programmes in detecting conditions associated with SCD among young individuals. Methods and results: We conducted a systematic review following PRISMA guidelines, with the protocol registered in PROSPERO (CRD42024540606). Original studies evaluating cardiovascular screening in young individuals were included, while studies exclusively involving competitive athletes were excluded. Nineteen studies encompassing 1 079 781 participants from multiple countries were finally analysed. Most studies (68%) were published recently and primarily targeted children and adolescents aged 6–19 years; 63% were assessed as having a low risk of bias. Screening modalities included electrocardiography (ECG) alone (26.3%), questionnaires alone (5.3%), and a combination of both (68.4%). Following second- or third-line investigations, the overall diagnostic yield for SCD-risk conditions was 1.4‰ (1.9‰ in the meta-analysis). The pooled prevalence, estimated using a random-effects model, was 2.23‰ (95% CI: 0.94–5.29‰), with extremely high heterogeneity among studies (I2 = 100%, P < 0.0001). Conclusion: Systematic cardiovascular screening may help identify young individuals at increased risk for SCD, providing a potentially meaningful diagnostic yield. However, the absence of long-term data on outcome and cost-effectiveness underscores the need for further research to refine screening protocols, assess sustainability, and inform evidence-based public health policies.

1 October 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
FBFrancesca Bonanni
Francesca Bonanni
GNGabrielle Norrish
Gabrielle Norrish
EFElla Field
Ella Field
ABAnnabelle Barnes
Annabelle Barnes
NMNina MacPherson
Nina MacPherson
Juan Pablo KaskiJuan Pablo Kaski
Juan Pablo Kaski